PF-Atlas › Clinical Trials › NCT03093974

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection.

CMS · ANZCTR · Phase 3

Registry ID
NCT03093974
Phase
Phase 3
Status
Completed
Drug / intervention
CMS
Mechanism
ANZCTR
Sponsor
Zambon SpA
Start
2017-06-06
Enrollment
377
Locations
85

About this trial

The objective of the trial was to investigate the effect of the use of inhaled CMS, administered b.i.d. via a specific nebuliser for 12 months, compared to placebo in subjects with NCFB chronically infected with P. aeruginosa on the annualised frequency of pulmonary exacerbations.

View NCT03093974 on ClinicalTrials.gov →

Explore related

All CMS trialsANZCTR mechanismAll IPF trials

Related trials

Ifenprodil — NCT04318704Inhaled mannitol — NCT00669331PTI-808 — NCT03251092BI 1819479 — NCT06335303AP01 — NCT06951217AZLI 75 mg three times a day — NCT00112359
Medical disclaimer. This page summarizes public trial data for NCT03093974 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.